大阪大学 · Medicine
Shogo Kobayashi 교수의 연구실은 간세포암과 담도암을 중심으로 한 간암의 발병 기전과 치료 전략을 연구하고 있습니다. 특히 Mcl-1 단백질의 인산화 조절 메커니즘을 통해 세포 사멸 조절과 암 성장의 분자 기전을 밝혀내고 있으며, exosomal microRNA를 이용한 간세포암의 전이 및 생물학적 마커 규명에도 주력하고 있습니다. 이는 재발 예측 및 개인화 치료 전략 개발에 기여할 잠재력을 지닌 연구입니다.
표시된 성과는 수집된 데이터 기준으로 산출되며, 일부 차이가 있을 수 있습니다.
Mcl-1 is an antiapoptotic Bcl-2 family member that is highly regulated and when dysregulated contributes to cancer. The Mcl-1 protein is phosphorylated at multiple sites in response to different signaling events. Phosphorylations at Thr163 (by ERK) and Ser159 (by glycogen-synthase kinase 3beta) have recently been shown to slow and enhance, respectively, Mcl-1 protein turnover. Phosphorylation is also known to be stimulated at other, as-yet uncharacterized sites in the G2/M phase of the cell cycl
Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related death. High recurrence rates after curative resection and the lack of specific biomarkers for intrahepatic metastases are major clinical problems. Recently, exosomal microRNAs (miRNAs) have been reported to have a role in the formation of the pre-metastatic niche and as promising biomarkers in patients with malignancy. Here we aimed to clarify the molecular mechanisms of intrahepatic metastasis and to identify a novel b
The comparison of the survival of the 2 groups revealed that adjuvant S-1 therapy may be superior to adjuvant GEM therapy after major hepatectomy for BTC.
